Nano-multilamellar lipid vesicles loaded with a recombinant form of the chikungunya virus E2 protein improve the induction of virus-neutralizing antibodies

2021 ◽  
pp. 102445
Author(s):  
Aléxia Adrianne Venceslau-Carvalho ◽  
Marianna Teixeira de Pinho Favaro ◽  
Lennon Ramos Pereira ◽  
Mônica Josiane Rodrigues-Jesus ◽  
Samuel Santos Pereira ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Chikungunya Virus ◽  
Lipid Vesicles ◽  
Recombinant Form ◽  
E2 Protein

Serological Responses in Patients Infected with Mayaro Virus and Evaluation of Cross-Protective Responses against Chikungunya Virus

2021 ◽  
Author(s):  
Nathen E. Bopp ◽  
Kara J. Jencks ◽  
Crystyan Siles ◽  
Carolina Guevara ◽  
Stalin Vilcarromero ◽  
...  
Keyword(s):  
Latin America ◽  
South America ◽  
Neutralizing Antibodies ◽  
Chikungunya Virus ◽  
Neutralization Test ◽  
Close Relative ◽  
Previous Exposure ◽  
Chikv Infection ◽  
The Caribbean ◽  
Mayaro Virus

Mayaro virus (MAYV) is an alphavirus endemic to both Latin America and the Caribbean. Recent reports have questioned the ability of MAYV and its close relative, Chikungunya virus (CHIKV), to generate cross-reactive, neutralizing antibodies to one another. Since CHIKV was introduced to South America in 2013, discerning whether individuals have cross-reactive antibodies or whether they have had exposures to both viruses previously has been difficult. Using samples obtained from people infected with MAYV prior to the introduction of CHIKV in the Americas, we performed neutralizing assays and observed no discernable neutralization of CHIKV by sera from patients previously infected with MAYV. These data suggest that a positive CHIKV neutralization test cannot be attributed to prior exposure to MAYV and that previous exposure to MAYV may not be protective against a subsequent CHIKV infection.

scholarly journals Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Emily M. Webb ◽  
Sasha R. Azar ◽  
Sherry L. Haller ◽  
Rose M. Langsjoen ◽  
Candace E. Cuthbert ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Chikungunya Virus ◽  
Semliki Forest Virus ◽  
Virus Disease ◽  
Cross Protection ◽  
Health Concern ◽  
Antigenic Relationship ◽  
Wild Type ◽  
Chikv Infection ◽  
Mayaro Virus

AbstractMayaro virus (MAYV) causes an acute febrile illness similar to that produced by chikungunya virus (CHIKV), an evolutionary relative in the Semliki Forest virus complex of alphaviruses. MAYV emergence is typically sporadic, but recent isolations and outbreaks indicate that the virus remains a public health concern. Given the close phylogenetic and antigenic relationship between CHIKV and MAYV, and widespread distribution of CHIKV, we hypothesized that prior CHIKV immunity may affect MAYV pathogenesis and/or influence its emergence potential. We pre-exposed immunocompetent C57BL/6 and immunocompromised A129 or IFNAR mice to wild-type CHIKV, two CHIKV vaccines, or a live-attenuated MAYV vaccine, and challenged with MAYV. We observed strong cross-protection against MAYV for mice pre-exposed to wild-type CHIKV, and moderately but significantly reduced cross-protection from CHIKV-vaccinated animals. Immunity to other alphavirus or flavivirus controls provided no protection against MAYV disease or viremia. Mechanistic studies suggested that neutralizing antibodies alone can mediate this protection, with T-cells having no significant effect on diminishing disease. Finally, human sera obtained from naturally acquired CHIKV infection cross-neutralized MAYV at high titers in vitro. Altogether, our data suggest that CHIKV infection can confer cross-protective effects against MAYV, and the resultant reduction in viremia may limit the emergence potential of MAYV.

scholarly journals A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis

mAbs ◽  
2015 ◽  
Vol 7 (6) ◽  
pp. 1178-1194 ◽  
Author(s):  
Shirley Lam ◽  
Min Nyo ◽  
Patchara Phuektes ◽  
Chow Wenn Yew ◽  
Yee Joo Tan ◽  
...  
Keyword(s):  
Chikungunya Virus ◽  
E2 Protein

scholarly journals Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer

2017 ◽  
Vol 91 (10) ◽  
Author(s):  
Yuhang Liu ◽  
Junhua Pan ◽  
Yongfei Cai ◽  
Nikolaus Grigorieff ◽  
Stephen C. Harrison ◽  
...  
Keyword(s):  
Viral Entry ◽  
Clinical Studies ◽  
Neutralizing Antibodies ◽  
Vaccine Development ◽  
Recombinant Form ◽  
Soluble Form ◽  
Compact Structure ◽  
Antigenic Properties ◽  
Hiv 1 ◽  
Gp140 Trimer

ABSTRACT The HIV-1 envelope spike [Env; trimeric (gp160)3 cleaved to (gp120/gp41)3] induces membrane fusion, leading to viral entry. It is also the viral component targeted by neutralizing antibodies. Vaccine development requires production, in quantities suitable for clinical studies, of a recombinant form that resembles functional Env. HIV-1 gp140 trimers—the uncleaved ectodomains of (gp160)3—from a few selected viral isolates adopt a compact conformation with many antigenic properties of native Env spikes. One is currently being evaluated in a clinical trial. We report here low-resolution (20 Å) electron cryomicroscopy (cryoEM) structures of this gp140 trimer, which adopts two principal conformations, one closed and the other slightly open. The former is indistinguishable at this resolution from those adopted by a stabilized, cleaved trimer (SOSIP) or by a membrane-bound Env trimer with a truncated cytoplasmic tail (EnvΔCT). The latter conformation is closer to a partially open Env trimer than to the fully open conformation induced by CD4. These results show that a stable, uncleaved HIV-1 gp140 trimer has a compact structure close to that of native Env. IMPORTANCE Development of any HIV vaccine with a protein component (for either priming or boosting) requires production of a recombinant form to mimic the trimeric, functional HIV-1 envelope spike in quantities suitable for clinical studies. Our understanding of the envelope structure has depended in part on a cleaved, soluble trimer, known as SOSIP.664, stabilized by several modifications, including an engineered disulfide. This construct, which is difficult to produce in large quantities, has yet to induce better antibody responses than those to other envelope-based immunogens, even in animal models. The uncleaved ectodomain of the envelope protein, called gp140, has also been made as a soluble form to mimic the native Env present on the virion surface. Most HIV-1 gp140 preparations are not stable, however, and have an inhomogeneous conformation. The results presented here show that gp140 preparations from suitable isolates can adopt a compact, native-like structure, supporting its use as a vaccine candidate.

scholarly journals Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand

2014 ◽  
Vol 11 (1) ◽  
pp. 183 ◽  
Author(s):  
Narong Nitatpattana ◽  
Kobkan Kanjanopas ◽  
Sutee Yoksan ◽  
Wichai Satimai ◽  
Narong Vongba ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Chikungunya Virus ◽  
Human Populations ◽  
North Eastern

scholarly journals First Imported Case of Chikungunya Virus Infection in a Travelling Canadian Returning from the Caribbean

2016 ◽  
Vol 2016 ◽  
pp. 1-5
Author(s):  
Christian Therrien ◽  
Guillaume Jourdan ◽  
Kimberly Holloway ◽  
Cécile Tremblay ◽  
Michael A. Drebot
Keyword(s):  
Virus Infection ◽  
Dengue Virus ◽  
Neutralizing Antibodies ◽  
Chikungunya Virus ◽  
Joint Stiffness ◽  
Clinical Feature ◽  
Chikv Infection ◽  
Imported Case ◽  
The Caribbean ◽  
Hands And Feet

This is the first Canadian case of Chikungunya virus (CHIKV) infection reported in a traveller returning from the Caribbean. Following multiple mosquito bites in Martinique Island in January 2014, the patient presented with high fever, headaches, arthralgia on both hands and feet, and a rash on the trunk upon his return to Canada. Initial serological testing for dengue virus infection was negative. Support therapy with nonsteroidal anti-inflammatory drugs was administered. The symptoms gradually improved 4 weeks after onset with residual arthralgia and morning joint stiffness. This clinical feature prompted the clinician to request CHIKV virus serology which was found to be positive for the presence of IgM and neutralizing antibodies. In 2014, over four hundred confirmed CHIKV infection cases were diagnosed in Canadian travellers returning from the Caribbean and Central America. Clinical suspicion of CHIKV or dengue virus infections should be considered in febrile patients with arthralgia returning from the recently CHIKV endemic countries of the Americas.

scholarly journals A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Pedro M. Folegatti ◽  
Kate Harrison ◽  
Lorena Preciado-Llanes ◽  
Fernando Ramos Lopez ◽  
Mustapha Bittaye ◽  
...  
Keyword(s):  
Single Dose ◽  
Neutralizing Antibodies ◽  
Chikungunya Virus ◽  
Phase 1 ◽  
Primary Objective ◽  
Open Label ◽  
Cell Responses ◽  
Single Intramuscular Injection ◽  
Secondary Objective ◽  
Vectored Vaccine

AbstractChikungunya virus (CHIKV) is a reemerging mosquito-borne virus that causes swift outbreaks. Major concerns are the persistent and disabling polyarthralgia in infected individuals. Here we present the results from a first-in-human trial of the candidate simian adenovirus vectored vaccine ChAdOx1 Chik, expressing the CHIKV full-length structural polyprotein (Capsid, E3, E2, 6k and E1). 24 adult healthy volunteers aged 18–50 years, were recruited in a dose escalation, open-label, nonrandomized and uncontrolled phase 1 trial (registry NCT03590392). Participants received a single intramuscular injection of ChAdOx1 Chik at one of the three preestablished dosages and were followed-up for 6 months. The primary objective was to assess safety and tolerability of ChAdOx1 Chik. The secondary objective was to assess the humoral and cellular immunogenicity. ChAdOx1 Chik was safe at all doses tested with no serious adverse reactions reported. The vast majority of solicited adverse events were mild or moderate, and self-limiting in nature. A single dose induced IgG and T-cell responses against the CHIKV structural antigens. Broadly neutralizing antibodies against the four CHIKV lineages were found in all participants and as early as 2 weeks after vaccination. In summary, ChAdOx1 Chik showed excellent safety, tolerability and 100% PRNT50 seroconversion after a single dose.

Sign in / Sign up

Export Citation Format

Share Document